22 research outputs found
Recommended from our members
The Supersymmetric Generalized Modified KdV Hierarchy and Odd Minimal Superconformal Field Theories Coupled to 2D Supergravity: 2
We further study the universal equations of the supersymmetric modified KdV (MKdV) hierarchy in its generalized form. We show that these equations describe the dynamical quantum equations of the odd series of N = 1 minimal (p,q) superconformal field theory coupled to N = 1 supergravity in particular those unitary series with p = 2k + 3, and q = 2k = 1. The string susceptibility of these models is {gamma}{sub sstr.}{sup (0)} = {minus}2/2k + 1. We demonstrate explicitly the cases k = 2; and k = 3. 10 refs
High Spin Gauge Fields and Two-Time Physics
All possible interactions of a point particle with background
electromagnetic, gravitational and higher-spin fields is considered in the
two-time physics worldline formalism in (d,2) dimensions. This system has a
counterpart in a recent formulation of two-time physics in non-commutative
field theory with local Sp(2) symmetry. In either the worldline or field theory
formulation, a general Sp(2) algebraic constraint governs the interactions, and
determines equations that the background fields of any spin must obey. The
constraints are solved in the classical worldline formalism (h-bar=0 limit) as
well as in the field theory formalism (all powers of h-bar). The solution in
both cases coincide for a certain 2T to 1T holographic image which describes a
relativistic particle interacting with background fields of any spin in (d-1,1)
dimensions. Two disconnected branches of solutions exist, which seem to have a
correspondence as massless states in string theory, one containing low spins in
the zero Regge slope limit, and the other containing high spins in the infinite
Regge slope limit.Comment: LaTeX 22 pages. Typos corrected in version
Marginal Deformations of Field Theories with AdS_4 Duals
We generate new AdS_4 solutions of D=11 supergravity starting from AdS_4 x
X_7 solutions where X_7 has U(1)^3 isometry. We consider examples where X_7 is
weak G_2, Sasaki-Einstein or tri-Sasakian, corresponding to d=3 SCFTs with
N=1,2 or 3 supersymmetry, respectively, and where the deformed solutions
preserve N=1,2 or 1 supersymmetry, respectively. For the special cases when X_7
is M(3,2), Q(1,1,1) or N(1,1)_I we identify the exactly marginal deformation in
the dual field theory. We also show that the volume of supersymmetric 5-cycles
of N(1,1)_I agrees with the conformal dimension predicted by the baryons of the
dual field theory.Comment: 28 pages, 2 figures; v2. typos correcte
Marginal Deformations with U(1)^3 Global Symmetry
We generate new 11-dimensional supergravity solutions from deformations based
on U(1)^3 symmetries. The initial geometries are of the form AdS_4 x Y_7, where
Y_7 is a 7-dimensional Sasaki-Einstein space. We consider a general family of
cohomogeneity one Sasaki-Einstein spaces, as well as the recently-constructed
cohomogeneity three L^{p,q,r,s} spaces. For certain cases, such as when the
Sasaki-Einstein space is S^7, Q^{1,1,1} or M^{1,1,1}, the deformed gravity
solutions correspond to a marginal deformation of a known dual gauge theory.Comment: 28pp; Refs. added and to appear in JHE
Duality and Spontaneously Broken Supergravity in Flat Backgrounds
It is shown that the super Higgs mechanism that occurs in a wide class of
models with vanishing cosmological constant (at the classical level) is
obtained by the gauging of a flat group which must be an electric subgroup of
the duality group. If the residual massive gravitinos which occur in the
partial supersymmetry breaking are BPS saturated, then the flat group is non
abelian. This is so for all the models obtained by a Scherk-Schwarz
supersymmetry breaking mechanism. If gravitinos occur in long multiplets, then
the flat groups may be abelian. This is the case of supersymmetry breaking by
string compactifications on an orientifold T^6/Z_2 with non trivial brane
fluxes.Comment: Version to appear on Nuclear Physics
Constrained Supermanifolds for AdS M-Theory Backgrounds
A long standing problem is the supergauge completion of AdS_4 x (G/H)_7 or
AdS_5 x (G/H)_5 backgrounds which preserve less then maximal supersymmetry. In
parallel with the supersolvable realization of the AdS_4 x S^7 background based
on Kappa-symmetry, we develop a technique which amounts to solving the
above-mentioned problem in a way useful for pure spinor quantization for
supermembranes and superstrings. Instead of gauge fixing some of the superspace
coordinates to zero, we impose an additional constraint on them reproducing the
simplifications of the supersolvable representations. The constraints are
quadratic, homogeneous, Sp(4,R)-covariant, and consistent from the quantum
point of view in the pure spinor approach. Here we provide the geometrical
solution which, in a subsequent work, will be applied to the membrane and the
superstring sigma models.Comment: LaTex, 47 pages, no figure
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
Introduction: The National Comprehensive Cancer Network guidelines recommend re-challenge with the first-line treatment for relapsed small cell lung cancer (SCLC) with chemotherapy-free interval (CTFI)=180 days. A phase II study (NCT02454972) showed remarkable antitumor activity in SCLC patients treated with lurbinectedin 3.2 mg/m2 1 -h intravenous infusion every 3 weeks as second-line therapy. We report results for the pre-planned subset of patients with CTFI = 180 days.
Material and Methods: Twenty patients aged =18 years with pathologically proven SCLC diagnosis, pretreated with only one prior platinum-containing line, no CNS metastases, and with CTFI = 180 days were evaluated. The primary efficacy endpoint was the overall response rate (ORR) assessed by the Investigators according to RECIST v1.1.
Results: ORR was 60.0 % (95 %CI, 36.1-86.9), with a median duration of response of 5.5 months (95 %CI, 2.9-11.2) and disease control rate of 95.0 % (95 %CI, 75.1-99.9). Median progression-free survival was 4.6 months (95 %CI, 2.6-7.3). With a censoring of 55.0 %, the median overall survival was 16.2 months (95 %CI, 9.6-upper level not reached). Of note, 60.9 % and 27.1 % of patients were alive at 1 and 2 years, respectively. The most common grade 3/4 adverse events and laboratory abnormalities were hematological disorders (neutropenia, 55.0 %; anemia; 10.0 % thrombocytopenia, 10.0 %), fatigue (10.0 %) and increased liver function tests (GGT, 10 %; ALT and AP, 5.0 % each). No febrile neutropenia was reported.
Conclusion: Lurbinectedin is an effective treatment for platinum-sensitive relapsed SCLC, especially in patients with CTFI = 180 days, with acceptable safety and tolerability. These encouraging results suggest that lurbinectedin can be another valuable therapeutic option rather than platinum re-challenge
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours
Background: Brivanib is a selective inhibitor of vascular endothelial growth factor and fibroblast growth factor (FGF) signalling. We performed a phase II randomised discontinuation trial of brivanib in 7 tumour types (soft-tissue sarcomas [STS], ovarian cancer, breast cancer, pancreatic cancer, non-small-cell lung cancer [NSCLC], gastric/esophageal cancer and transitional cell carcinoma [TCC]). Patients and methods: During a 12-week open-label lead-in period, patients received brivanib 800 mg daily and were evaluated for FGF2 status by immunohistochemistry. Patients with stable disease at week 12 were randomised to brivanib or placebo. A study steering committee evaluated week 12 response to determine if enrolment in a tumour type would continue. The primary objective was progression-free survival (PFS) for brivanib versus placebo in patients with FGF2-positive tumours. Results: A total of 595 patients were treated, and stable disease was observed at the week 12 randomisation point in all tumour types. Closure decisions were made for breast cancer, pancreatic cancer, NSCLC, gastric cancer and TCC. Criteria for expansion were met for STS and ovarian cancer. In 53 randomised patients with STS and FGF2-positive tumours, the median PFS was 2.8 months for brivanib and 1.4 months for placebo (hazard ratio [HR]: 0.58, p = 0.08). For all randomised patients with sarcomas, the median PFS was 2.8 months (95% confidence interval [CI]: 1.4â4.0) for those treated with brivanib compared with 1.4 months (95% CI: 1.3â1.6) for placebo (HR = 0.64, 95% CI: 0.38â1.07; p = 0.09). In the 36 randomised patients with ovarian cancer and FGF2-positive tumours, the median PFS was 4.0 (95% CI: 2.6â4.2) months for brivanib and 2.0 months (95% CI: 1.2â2.7) for placebo (HR: 0.56, 95% CI: 0.26â1.22). For all randomised patients with ovarian cancer, the median PFS in those randomised to brivanib was 4.0 months (95% CI: 2.6â4.2) and was 2.0 months (95% CI: 1.2â2.7) in those randomised to placebo (HR = 0.54, 95% CI: 0.25â1.17; p = 0.11). Conclusion: Brivanib demonstrated activity in STS and ovarian cancer with an acceptable safety profile. FGF2 expression, as defined in the protocol, is not a predictive biomarker of the efficacy of brivanib